Want to join the conversation?
Biopharmaceutical company $BXLT said it has launched ADYNOVATE, a new treatment to control bleeding episodes in adult patients with Hemophilia A with a simple twice-weekly dosing schedule, in the U.S. Market. ADYNOVATE was developed through a collaboration with $NKTR and was approved by U.S. FDA in Nov. 2015.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.